Alnylam Grants Bio-Rad License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market
"Execution of this license agreement with Bio-Rad, a global leader in the life science research community, continues to underscore the value of the Kreutzer-Limmer patent family as a critical component of fundamental intellectual property in the field of RNAi," said Roland Kreutzer, Ph.D., Managing Director of Alnylam Europe AG. "This agreement brings the number of licenses that Alnylam has granted to more than 20, including 13 with research product suppliers. In fact, we believe that over 75 percent of industrial sales of siRNAs for research purposes are currently being made under access to Alnylam's intellectual property."
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.